Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00843375 · ClinicalTrials.gov registry record
Evaluation of Stool Based Markers for the Early Detection of Colorectal Cancers and Adenomas
A clinical trial of Colonic Neoplasms, sponsored by University of Michigan Rogel Cancer Center.
- Recruiting
- Registry status
- 1,200
- Enrollment target
- 13
- Study locations
NCT00843375 is a study of Colonic Neoplasms that is actively recruiting participants, run by University of Michigan Rogel Cancer Center. The registered enrollment target is 1,200 participants, below the 1,437-participant average among 14 other Colonic Neoplasms trials with a reported enrollment target (16% lower). The trial reports 13 study locations across 13 states.
The verdict
NCT00843375, a study of Colonic Neoplasms, is actively recruiting participants, sponsored by University of Michigan Rogel Cancer Center.
- RECRUITING
- Registry status
- 1,200 participants
- Enrollment target
- 13
- Study locations
Study Summary
Colon cancer is the second most common cancer in men and women. It is a disease that can be prevented if it is found early. Colonoscopy is still the best screening tool for colon cancer and the polyps that turn into colon cancer. However, due to a variety of factors, including affordability, time, and age, not all patients are able to be screened. Researchers are working on other options for early detection that are as accurate as colonoscopy. The purpose of this study if to determine if stool or blood can be used to detect colon cancers as early or earlier than colonoscopy. The researchers plan to use these samples to learn about specific proteins (also known as biomarkers) that may indicate colon polyps, colon cancer or an increased risk of developing colon cancer. In order to learn more about preventing and detecting colon and rectal cancer, we are collecting samples from subjects with cancer, adenomas, and colonoscopies who may be at risk for polyps.
Conditions Studied
Study Locations (13)
California
- Cedars-Sinai Medical Center - Los Angeles
Illinois
- Carle Cancer Center - Urbana
Massachusetts
- Dana Farber Cancer Institute - Boston
Michigan
- University of Michigan - Ann Arbor
Minnesota
- University of Minnesota - Minneapolis
New York
- NYU Langone Health - New York
North Carolina
- University of North Carolina - Chapel Hill
Oregon
- Oregon Health and Science University - Portland
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,200 participants |
| Start Date | 2019-08-07 |
| Est. Completion | 2028-03 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00843375
The ClinicalTrials.gov registry entry for NCT00843375 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 1,200 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,437-participant average among 14 other Colonic Neoplasms trials with a reported enrollment target (16% lower). The listed sponsor is University of Michigan Rogel Cancer Center, which has 292 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Colonic Neoplasms appearing as the primary indexed condition, and to 0 interventions.
NCT00843375 reports 13 study locations spanning 13 distinct geographic areas - top geographies include California, Illinois, Massachusetts.
Frequently Asked Questions
What is clinical trial NCT00843375 about?
NCT00843375 is a clinical study titled "Evaluation of Stool Based Markers for the Early Detection of Colorectal Cancers and Adenomas". Colon cancer is the second most common cancer in men and women. It is a disease that can be prevented if it is found early. Colonoscopy is still the best screening tool for colon cancer and the polyps that turn into colon cancer. However, due to a variety of factors, including affordability, time, a...
What is the current status of trial NCT00843375?
This trial is currently recruiting. The enrollment target is 1,200 participants. The study started on 2019-08-07. Estimated completion is 2028-03.
What conditions does trial NCT00843375 study?
This clinical trial studies the following conditions: Colonic Neoplasms.
Who is sponsoring clinical trial NCT00843375?
This trial is sponsored by University of Michigan Rogel Cancer Center, which has 292 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00843375 being conducted?
This trial has 13 study locations across California, Illinois, Massachusetts, Michigan, Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Colonic Neoplasms
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Strategies for Optimizing a Mailed FIT Program in Appalachia
RECRUITING · NA
-
Adaptive Randomization of Aerobic Exercise During Chemotherapy in Colon Cancer
RECRUITING · NA
-
Anti-Mesothelin TNaive/SCM hYP218 (TNhYP218) CAR T Cells in Participants With Mesothelin-Expressing Solid Tumors Including Mesothelioma
RECRUITING · Phase 1
-
Study of Perioperative Dostarlimab in Participants With Untreated T4N0 or Stage III dMMR/MSI-H Resectable Colon Cancer
RECRUITING · Phase 3
-
Effects of Aerobic Exercise on Skeletal Muscle Remodeling in Colorectal Cancer
RECRUITING · NA
-
Ascertainment of Peripheral Blood or Saliva Samples for Genetic Epidemiology Studies of Familial Cancers
ACTIVE NOT RECRUITING
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.